The Regulatory Boundary That Defines a Medical Product
Australia has one of the Asia-Pacific region’s more developed frameworks for software as a medical device, and the Therapeutic Goods Administration is using 2026 to make the boundary unmistakable. Digital therapeutics are not fitness trackers with a clinical gloss. The TGA defines them as evidence-based software products that deliver medical interventions intended to prevent, manage or treat a disease, disorder or injury. That definition carries legal weight: DTx products must be included in the Australian Register of Therapeutic Goods before they can be supplied in Australia, unless an exclusion or exemption applies.
The distinction matters commercially as much as clinically. Wellness apps that support general health and lifestyle goals are not regulated as medical devices, while DTx products are expected to carry clinical evidence and specific intended-purpose claims. For developers, the ARTG pathway is not a formality. It demands documented clinical rationale, safety information and clear product information so that clinicians and patients understand how the software should be used.
Why 2026 Is a Pivotal Year for Digital Mental Health Tools
The TGA has moved from general guidance to active consultation on digital mental health tools, a category that includes apps, websites and chatbots offering assessment, therapy or self-management support. Many of these tools are regulated as medical devices, but some have sat inside an exclusion introduced in 2021. The TGA’s review found that the exclusion may no longer be appropriate for the functionality and risk profile of some tools, particularly as artificial intelligence becomes more embedded in clinical decision support.
The consultation, which runs through late 2026, asks whether the exclusion should be kept, removed or modified. That question has direct consequences for developers building AI-enabled mental health products. A tool that screens, triages or recommends treatment is moving toward the regulated side of the line, while administrative software such as scheduling or transcription is less likely to be caught. The TGA has also signalled that SaMD compliance is a priority for its 2026–27 enforcement activities.
Clinical Evidence Becomes the Price of Admission
The regulatory shift is forcing a more mature conversation about evidence. Australia is not short of digital mental health programs with trial data. THIS WAY UP, a clinician-prescribable platform developed through St Vincent’s Hospital Sydney, offers online cognitive behavioural therapy programs for anxiety, depression, insomnia and chronic pain, supported by 36 randomised controlled trials and more than 20 real-world publications. Its existence shows that the evidence base can be built, but it also highlights the gap between a research-backed program and a routinely funded clinical service.
For the TGA, the central issue is intended use. A product that claims to treat generalised anxiety disorder is making a medical claim, and that claim must be supported by evidence proportionate to the risk. The 2026 consultation is effectively asking the market to decide whether low-risk digital mental health tools should continue to operate outside device regulation, or whether the growing complexity of AI-driven tools has made that exclusion untenable.
What This Means for Clinicians and Patients
Clinicians are being asked to become more discerning consumers of digital tools. A product listed on the ARTG has crossed a regulatory threshold that a wellness app has not. That does not make every listed product clinically superior in every context, but it does provide a baseline of regulatory accountability. Patients, meanwhile, are encountering a crowded app marketplace in which the language of therapy is used loosely. The TGA’s sharper boundary is designed to make that language mean something enforceable. The practical effect is that Australia’s digital therapeutics sector is being pushed toward a simple proposition: if a product wants to be part of patient care, it must be able to show what it does, for whom, and on what evidence.
